Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.
Company Size
51-200
Company Stage
Series B
Total Funding
$115.5M
Headquarters
Herzliya, Israel
Founded
2018
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?